Asston Pharmaceuticals IPO Closes at 173.53× Subscription; Record Retail and HNI Participation
By Shishta Dutta | Published at: Jul 11, 2025 06:38 PM IST
Mumbai, July 11, 2025 — The SME IPO of Asston Pharmaceuticals Limited closed with extraordinary investor response, posting a final subscription of 173.53 times by 5:09 PM on the last day of bidding. Priced at an issue price of ₹123 per share, the issue attracted unprecedented demand from retail investors, HNIs, and institutional players, with every investor segment significantly oversubscribed.
Final Subscription Status (as of July 11, 2025 – 5:09 PM)
| Category | Shares Offered | Shares Bid | Subscription (x) |
|---|---|---|---|
| Qualified Institutional Buyers (QIBs) | 4,25,000 | 3,64,49,000 | 85.76× |
| Non-Institutional Investors (NII) | 3,22,000 | 11,37,10,000 | 353.14× |
| — NIIs (> ₹10 lakh) | 2,15,000 | 9,12,62,000 | 424.47× |
| — NIIs (≤ ₹10 lakh) | 1,07,000 | 2,25,61,000 | 210.85× |
| Retail Individual Investors (RII) | 7,46,000 | 12,83,58,000 | 172.06× |
| Total | 14,93,000 | 27,85,17,000 | 186.55× |
IPO Timeline
The post-issue timeline has been confirmed as follows:
| Event | Date |
|---|---|
| Allotment Finalisation | July 14, 2025 |
| Refund Initiation | July 15, 2025 |
| Demat Credit | July 15, 2025 |
| Listing on BSE SME | July 16, 2025 |
IPO Summary
| Detail | Information |
|---|---|
| Issue Size | 22,41,000 equity shares |
| Issue Price | ₹123 per share |
| Lot Size | 1000 shares |
| Lead Manager | Sobhagya Capital Options Ltd |
| Registrar | Maashitla Securities Pvt Ltd |
| Exchange | BSE SME |
Market Outlook
With record oversubscription across all categories, Asston Pharmaceuticals is expected to witness strong listing interest. Investors can expect allotment updates on July 14, while listing is slated for July 16, subject to final SEBI and BSE clearances.
About the Company
Asston Pharmaceuticals Limited is engaged in the manufacture and export of pharmaceutical formulations and nutraceuticals. With a production base in Ambernath, Maharashtra, and partnerships with WHO-GMP-certified facilities, the company caters to markets in Africa and Asia.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
